Lv3
280 积分 2025-03-22 加入
514MO The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)
1个月前
已关闭
Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease
1个月前
已完结
Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China
1个月前
已完结
Cancer-related fatigue: an overview
1个月前
已完结
Clinical Efficacy and Safety of Anti-IL-17 Agents for the Treatment of Patients with Psoriasis
1个月前
已关闭
Clinical Efficacy and Safety of Anti-IL-17 Agents for the Treatment of Patients with Psoriasis
1个月前
已关闭
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease
1个月前
已完结
Th2 inflammatory responses in the development of nasal polyps and chronic rhinosinusitis
1个月前
已完结
Ivonescimab: First Approval
1个月前
已完结
皖公网安备34019202002308
